ZA200709903B - Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts - Google Patents

Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts

Info

Publication number
ZA200709903B
ZA200709903B ZA200709903A ZA200709903A ZA200709903B ZA 200709903 B ZA200709903 B ZA 200709903B ZA 200709903 A ZA200709903 A ZA 200709903A ZA 200709903 A ZA200709903 A ZA 200709903A ZA 200709903 B ZA200709903 B ZA 200709903B
Authority
ZA
South Africa
Prior art keywords
benzimidazol
methylpiperazin
quinolin
fluoro
crystalline
Prior art date
Application number
ZA200709903A
Other languages
English (en)
Inventor
Okhamafe Augustus
Chou Joyce
Gullapalli Rampurna
Harwood Eric
Ryckman David
Zhu Shuguang
Shang Xiao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37102961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200709903(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200709903B publication Critical patent/ZA200709903B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200709903A 2005-05-23 2007-11-16 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts ZA200709903B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68399905P 2005-05-23 2005-05-23

Publications (1)

Publication Number Publication Date
ZA200709903B true ZA200709903B (en) 2008-12-31

Family

ID=37102961

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709903A ZA200709903B (en) 2005-05-23 2007-11-16 Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts

Country Status (21)

Country Link
US (2) US20110178097A1 (ru)
EP (3) EP1904480A2 (ru)
JP (2) JP2008542289A (ru)
KR (1) KR101368519B1 (ru)
CN (2) CN102070614B (ru)
AU (1) AU2006249847B2 (ru)
BR (1) BRPI0611375A2 (ru)
CA (1) CA2609353C (ru)
EC (1) ECSP078030A (ru)
HK (1) HK1152294A1 (ru)
IL (2) IL187487A0 (ru)
MA (1) MA29532B1 (ru)
MX (1) MX2007014782A (ru)
NO (1) NO20076635L (ru)
NZ (1) NZ563692A (ru)
PH (1) PH12013500773A1 (ru)
RU (1) RU2425041C2 (ru)
SG (1) SG154451A1 (ru)
TN (1) TNSN07434A1 (ru)
WO (1) WO2006127926A2 (ru)
ZA (1) ZA200709903B (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567550A (en) * 2005-11-29 2011-08-26 Novartis Ag Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
PE20091628A1 (es) * 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
BRPI0913843A2 (pt) * 2008-07-03 2015-10-20 Novartis Ag processo de granulação por fusão
RU2012145468A (ru) * 2010-03-26 2014-05-10 Новартис Аг Получение гидратированных полиморфов соли молочной кислоты 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
JP2013525291A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 肝がんの治療に使用するための有機化合物
CN102834094B (zh) 2010-04-16 2015-05-06 诺华有限公司 有机化合物的组合产品及其制药用途
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
AU2012229107A1 (en) 2011-03-17 2013-09-19 Novartis Ag FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
AU2012255148A1 (en) 2011-05-19 2013-11-07 Novartis Ag 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1H - benzimidazol - 2 - yl] - 1H - quinolin-2-one for use in the treatment of adenoid cystic carcinoma
MX2014003182A (es) * 2011-09-15 2014-09-22 Novartis Ag Uso de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidaz ol-2-il]-1h-quinolin-2-ona en el tratamiento de cancer en pacientes con insuficiencia hepática moderada.
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
AU2013215251A1 (en) 2012-01-31 2014-08-14 Novartis Ag Combination of a RTK inhibitor with an anti - estrogen and use thereof for the treatment of cancer
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
IN2014DN10801A (ru) 2012-07-11 2015-09-04 Novartis Ag
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
CN103804349A (zh) * 2012-11-01 2014-05-21 杨子娇 一类治疗青光眼的化合物及其用途
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
ES2919346T3 (es) * 2014-03-06 2022-07-26 Elanco Animal Health Incorporated Forma cristalina x2 de grapiprant
WO2016027781A1 (ja) 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
KR20220162823A (ko) 2014-09-26 2022-12-08 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
TWI707851B (zh) * 2015-09-17 2020-10-21 日商大鵬藥品工業股份有限公司 哌嗪化合物的新穎結晶
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
KR20200020888A (ko) 2017-06-27 2020-02-26 얀센 파마슈티카 엔.브이. 신규 퀴놀리논 화합물
CA3091153A1 (en) 2018-03-28 2019-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
EA202190826A1 (ru) 2018-09-21 2021-06-16 Янссен Фармацевтика Нв Лечение холангиокарциномы
DE202019101126U1 (de) 2019-02-27 2019-03-06 Hgz Schutz Gmbh Wespenschutz
CA3130773A1 (en) 2019-03-29 2020-10-08 Peter Marie Z. De Porre Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CA3130460A1 (en) 2019-03-29 2020-10-08 Anne Elizabeth O'HAGAN Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CN113993858B (zh) * 2019-04-30 2024-05-28 北京泰德制药股份有限公司 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
BR112022015827A2 (pt) 2020-02-12 2022-10-04 Janssen Pharmaceutica Nv Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco
MX2023002980A (es) 2020-09-14 2023-06-06 Janssen Pharmaceutica Nv Terapias de combinación de inhibidores del fgfr.
BR112023023935A2 (pt) 2021-05-19 2024-01-30 Janssen Pharmaceutica Nv Inibidores de tirosina quinase de fgfr para o tratamento de tumores sólidos avançados
WO2024170495A1 (en) 2023-02-13 2024-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
DE3248043A1 (de) 1982-12-24 1984-06-28 Bayer Ag, 5090 Leverkusen Fluorogene phosphorsaeureester, verfahren zu deren herstellung sowie verfahren und mittel zum nachweis und zur fluorometrischen bestimmung von phosphaten
DE3634066A1 (de) * 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
WO1995018801A1 (en) 1994-01-08 1995-07-13 Rhone-Poulenc Agriculture Ltd. Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU2103097A (en) 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
JP4373497B2 (ja) * 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
SE506547C2 (sv) 1996-06-20 1998-01-12 Asea Brown Boveri Förfarande och anordning för att detektera feltändning hos en förbränningsmotor
ATE300521T1 (de) 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
ES2182327T3 (es) 1997-06-02 2003-03-01 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos.
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1005470B1 (en) 1997-08-22 2007-08-01 AstraZeneca AB Oxindolylquinazoline derivatives as angiogenesis inhibitors
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
AU3363599A (en) 1998-03-26 1999-10-18 Max-Planck Institut Fur Biochemie Heterocyclic families of compounds for the modulation of tyrosine protein kinase
PL343112A1 (en) 1998-03-31 2001-07-30 Warner Lambert Co Quinolones as serine protease inhibitors
CA2328893A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6174912B1 (en) * 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
GB9818310D0 (en) 1998-08-22 1998-10-14 Koninkl Philips Electronics Nv Thin film transistors and their manufacture
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
JP2003171280A (ja) 1999-06-07 2003-06-17 Fujisawa Pharmaceut Co Ltd 抗腫瘍効果増強剤
KR100298572B1 (ko) * 1999-08-19 2001-09-22 박찬구 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법
ATE286045T1 (de) * 1999-10-19 2005-01-15 Merck & Co Inc Tyrosin kinaseinhibitoren
AU778042B2 (en) * 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
UA73976C2 (ru) 2000-02-15 2005-10-17 Суджен, Інк. Замещенные пирролом 2-индолиноны, фармацевтическая композиция, способ модуляции каталитической активности протеинкиназы и способ лечения или профилактики заболевания, связанного с протеинкиназой
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001293233A1 (en) * 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
AU2001288432A1 (en) * 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
KR100728797B1 (ko) * 2000-09-11 2007-06-19 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
EP1444041A2 (en) 2001-09-21 2004-08-11 Solvias AG Sealing system with flow channels
EP1447405A4 (en) 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7470709B2 (en) * 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7838527B2 (en) * 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US6774327B1 (en) 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
EP1699421B1 (en) * 2003-11-07 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Lactate salts of quinolinone compounds and their pharmaceutical use
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
JP5371246B2 (ja) * 2005-01-27 2013-12-18 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移した腫瘍の治療
SI1845990T1 (sl) * 2005-01-27 2012-01-31 Novartis Vaccines & Diagnostic Zdravljenje metastaziranih tumorjev
MX2007014612A (es) * 2005-05-18 2008-01-17 M & G Polimeri Italia Spa Composicion de poliester.

Also Published As

Publication number Publication date
WO2006127926A3 (en) 2007-01-18
PH12013500773A1 (en) 2014-11-10
IL223350A0 (en) 2013-02-03
JP2013224299A (ja) 2013-10-31
RU2007147427A (ru) 2009-06-27
ECSP078030A (es) 2008-01-23
AU2006249847B2 (en) 2012-12-20
NZ563692A (en) 2011-04-29
EP1904480A2 (en) 2008-04-02
SG154451A1 (en) 2009-08-28
AU2006249847A1 (en) 2006-11-30
CA2609353A1 (en) 2006-11-30
US8614216B2 (en) 2013-12-24
WO2006127926A2 (en) 2006-11-30
MX2007014782A (es) 2008-02-19
CA2609353C (en) 2015-04-28
CN101218228A (zh) 2008-07-09
RU2425041C2 (ru) 2011-07-27
EP2266974A1 (en) 2010-12-29
CN102070614A (zh) 2011-05-25
BRPI0611375A2 (pt) 2010-08-31
US20110178097A1 (en) 2011-07-21
US20120208825A1 (en) 2012-08-16
EP2270000A1 (en) 2011-01-05
NO20076635L (no) 2008-02-25
HK1152294A1 (en) 2012-02-24
CN102070614B (zh) 2014-01-15
EP2270000B1 (en) 2015-07-29
JP2008542289A (ja) 2008-11-27
IL187487A0 (en) 2008-02-09
TNSN07434A1 (en) 2009-03-17
MA29532B1 (fr) 2008-06-02
KR20080039845A (ko) 2008-05-07
KR101368519B1 (ko) 2014-02-27

Similar Documents

Publication Publication Date Title
IL223350A0 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
HK1147492A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4- methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts 4--5--3-[5-(4--1-)-1h--2-]-2(1h)-
HK1118553A1 (en) Method of preparing esomeprazole and salts thereof
IL242267A0 (en) Solid citrate and tartrate salts of iv– dpp inhibitors
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
EP1871219A4 (en) METHODS AND SYSTEMS FOR PSYCHOPHYSIOLOGICAL AND PHYSIOLOGICAL CONTROL AND USES THEREOF
PL2103214T3 (pl) Zastosowanie związków chinoliny, lub ich soli, jako substancji czynnych w środkach do traktowania gleby lub zaprawiania nasion oraz sposób kontrolowania chorób roślin
PL1760156T3 (pl) Materiały i sposoby wydajnej produkcji kwasu mlekowego
ZA200809531B (en) Use of selected lactic acid bacteria for reducing infantile colic
EP2136824A4 (en) USE OF SELECTED MILKY ACID BACTERIA TO REDUCE ATHEROSCLEROSIS
EP2094665A4 (en) PREPARATION OF MONTELUKAST AND ITS SALTS
EP1988155A4 (en) LACTIC ACID BACTERIUM CAPABLE OF PRODUCING AMINO-ACUTE ACID
PL1937407T3 (pl) Roztwory bezwodnych soli lantanowców i ich otrzymywanie
EP2215050A4 (en) PROCESS FOR THE PREPARATION OF 2-HYDROXY-5-PHENYL ALKYLAMINOBENZOESÄUREDERIVATEN AND THEIR SALTS
PT1833810T (pt) Modificações cristalinas de n-alfa-(2,4,6-triisopropil-fenilsulfonil)-3-hidroxiamidino-(l)-fenilalanina-4--etoxicarbonilpiperazida e/ou seus sais
EP2077994A4 (en) CRYSTALLINE WATER-FREE S - (-) - AMLODIPINADIPINIC ACID SALT AND METHOD FOR THE PRODUCTION THEREOF
TH0901001214A (th) รูปแบบที่เป็นผลึก และสองรูปแบบที่เป็นซอลเวทของเกลือ 4-อะมิโน-5-ฟลูออโร-3-[5-(4-เมทธิลพิเพอราซิน-1-อิล)-1h-เบนซิมิดาซอล-2-อิล]ควิโนลิน-2(1h)-โอน แลคติก แอซิด
TN2010000418A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
NZ602758A (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
IL185436A0 (en) Methods and systems for physiological and psycho-physiological monitoring and uses thereof
AU2006905312A0 (en) Relaxing sleep enhancer for babies and pets